PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Acquired by Fmr LLC

Fmr LLC increased its stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 11.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,159,208 shares of the company’s stock after acquiring an additional 866,328 shares during the period. Fmr LLC owned about 0.16% of PROCEPT BioRobotics worth $656,979,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Lord Abbett & CO. LLC raised its position in shares of PROCEPT BioRobotics by 45.3% in the third quarter. Lord Abbett & CO. LLC now owns 748,555 shares of the company’s stock worth $59,974,000 after acquiring an additional 233,430 shares during the period. Perpetual Ltd purchased a new position in shares of PROCEPT BioRobotics in the 4th quarter valued at about $66,972,000. Oak Ridge Investments LLC raised its holdings in PROCEPT BioRobotics by 24.0% in the 4th quarter. Oak Ridge Investments LLC now owns 30,059 shares of the company’s stock worth $2,420,000 after purchasing an additional 5,817 shares during the period. SG Americas Securities LLC boosted its position in PROCEPT BioRobotics by 295.8% during the fourth quarter. SG Americas Securities LLC now owns 6,598 shares of the company’s stock worth $531,000 after purchasing an additional 4,931 shares in the last quarter. Finally, Chicago Capital LLC increased its position in shares of PROCEPT BioRobotics by 44.5% in the fourth quarter. Chicago Capital LLC now owns 379,582 shares of the company’s stock valued at $30,564,000 after buying an additional 116,931 shares in the last quarter. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

PROCEPT BioRobotics Trading Down 4.0 %

Shares of PRCT stock opened at $48.82 on Wednesday. PROCEPT BioRobotics Co. has a fifty-two week low of $47.04 and a fifty-two week high of $103.81. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The stock’s fifty day moving average is $62.34 and its two-hundred day moving average is $76.25. The firm has a market capitalization of $2.68 billion, a P/E ratio of -25.04 and a beta of 1.09.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The business had revenue of $68.24 million during the quarter, compared to analysts’ expectations of $66.79 million. Research analysts expect that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

Insider Transactions at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 5,475 shares of the firm’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $312,403.50. Following the completion of the sale, the chief executive officer now directly owns 173,070 shares of the company’s stock, valued at $9,875,374.20. This trade represents a 3.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Kevin Waters sold 733 shares of the business’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the transaction, the chief financial officer now directly owns 107,991 shares in the company, valued at approximately $6,161,966.46. The trade was a 0.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,455 shares of company stock worth $368,322 in the last ninety days. Insiders own 17.40% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on PRCT shares. Morgan Stanley decreased their target price on PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Truist Financial reaffirmed a “buy” rating and set a $90.00 price objective (down from $105.00) on shares of PROCEPT BioRobotics in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, PROCEPT BioRobotics presently has an average rating of “Moderate Buy” and a consensus target price of $94.29.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).